ArticleLiver international : official journal of the International Association for the Study of the Liver2025
Neutrophil Extracellular Traps Are Not Linked to Decompensation, ACLF, or Death in Clinically Stable Patients With ACLD.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell Sequencing Reveals Neutrophil Extracellular Traps in Association with Endotheliopathy and Immunothrombosis in Hepatitis B Virus-related Acute-on-chronic Liver Failure.Journal of clinical and translational hepatology · 2026Article
- Neutrophil Extracellular Traps Are Not Linked to Decompensation, ACLF, or Death in Clinically Stable Patients With ACLD.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND AND
aimsNeutrophil extracellular traps (NETs) are part of the body's innate immune response. In animal models, NETs aggravated liver injury and promoted disease progression/portal hypertension by the formation of (micro)thrombi leading to parenchymal extinction. This study aimed to investigate NETosis in patients with clinically stable advanced chronic liver disease (ACLD).
methodsWe evaluated stable ACLD patients undergoing hepatic venous pressure gradient (HVPG) measurement in whom an extensive panel of laboratory tests related to coagulation and NET biomarkers was assessed in plasma. Hepatic decompensation/liver-related death (LRD) as well as the development of ACLF/LRD were the outcomes of interest.
results194 patients (70 compensated/124 decompensated; mean Child-Turcotte-Pugh score (CTP): 7 ± 2 points; mean HVPG: 17 ± 6 mmHg) were included. Compared to healthy controls (n = 29), levels of cell-free DNA (cf-DNA) were higher (0.88 [IQR 0.84-0.93] vs. 0.94 [IQR 0.88-1.03] μg/mL; p = 0.001) in ACLD, whereas myeloperoxidase-DNA (MPO-DNA) values were similar (0.32 [IQR 0.17-0.54] vs. 0.39 [IQR 0.18-0.76] AU; p = 0.400). Factor XIII activity levels, soluble P-selectin, and cf-DNA but not MPO-DNA levels were linked to HD/LRD and/or ACLF/LRD in univariable analysis. However, none of these tests were associated with the aforementioned outcomes after adjusting for established prognostic indicators.
conclusionPatients with stable ACLD showed increased cf-DNA levels (i.e., NETosis, but also apoptosis/necrosis). However, MPO-DNA as a NETosis-specific marker was comparable to healthy controls. NETosis does not appear to drive disease progression in clinically stable ACLD as it was not linked to endpoints, thereby questioning whether findings obtained in animal models are translatable to humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.